Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, ...

The study demonstrates that this RNAi approach shuts down vital fungal genes, thereby inhibiting pathogen growth - a ...

Home > Pressemitteilung: Major Progress in the Development of ...

Silexion Therapeutics completes development plan for next-generation siRNA candidate SIL204; plans to present at 2025 NeauxCancer Conference: Grand Cayman, Cayman Islands Tuesday, ...

Fan Kelong and Yan Xiyun from the Institute of Biophysics of the Chinese Academy of Sciences introduces a novel ferritin-based delivery system for small interfering RNA (siRNA) targeting ...

Bakka keenya sirrii taʼe adda baasuuf, saʼaatii sirrii taʼe beekuu qabna. GPS'n kan hojjetu mallattoo saatalaayitii ...

Merger Completion: On August 15, 2024, Silexion completed its business combination with Moringa Acquisition Corp, becoming a publicly traded company on Nasdaq under the ticker “SLXN.” This strategic ...

Arrowhead (ARWR) announced preclinical results on ARO-ALK7, the company’s investigational RNA interference therapeutic ... Co-treatment of tirzepatide and ALK7 siRNA had additive effects on ...

RNAi (RNA interference) is a biological process in which RNA molecules—microRNA (miRNA) and small interfering RNA (siRNA)—inhibit gene expression, typically by binding to messenger RNA (mRNA ...

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based ... for the development of an advanced siRNA formulation to enhance cancer treatment.